RAPT Therapeutics reported a net loss of $14.6 million for the third quarter of 2020, compared to a net loss of $10.0 million for the third quarter of 2019. Research and development expenses increased to $12.9 million, and general and administrative expenses increased to $3.2 million. The company had cash and cash equivalents and marketable securities of $122.8 million as of September 30, 2020.